These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19534585)

  • 1. Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients.
    Vincenzi B; Santini D; Loupakis F; Addeo R; Rojas Llimpe FL; Baldi GG; Di Fabio F; Del Prete S; Pinto C; Falcone A; Tonini G
    Expert Opin Biol Ther; 2009 Aug; 9(8):945-9. PubMed ID: 19534585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.
    Santini D; Vincenzi B; Adamo V; Addeo R; Fusco V; Russo A; Montemurro F; Roato I; Redana S; Lanzetta G; Satolli MA; Berruti A; Leoni V; Galluzzo S; Antimi M; Ferraro G; Rossi M; Del Prete S; Valerio MR; Marra M; Caraglia M; Tonini G
    Oncol Rep; 2011 Jun; 25(6):1545-8. PubMed ID: 21455582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
    Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
    J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.
    Pfeiffer P; Nielsen D; Yilmaz M; Iversen A; Vejlø C; Jensen BV
    Acta Oncol; 2007; 46(5):697-701. PubMed ID: 17562448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
    J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab-induced skin reactions are suppressed by cigarette smoking in patients with advanced colorectal cancer.
    Kajizono M; Saito M; Maeda M; Yamaji K; Fujiwara S; Kawasaki Y; Matsunaga H; Sendo T
    Int J Clin Oncol; 2013 Aug; 18(4):684-8. PubMed ID: 22678464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
    Vincenzi B; Santini D; Galluzzo S; Russo A; Fulfaro F; Silletta M; Battistoni F; Rocci L; Zobel BB; Adamo V; Dicuonzo G; Tonini G
    Clin Cancer Res; 2008 Jul; 14(13):4219-24. PubMed ID: 18594003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
    Gamucci T; Nelli F; Cianci G; Grassi G; Moscetti L; Sperduti I; Zeuli M; Cortesi E; D'Auria G; Pollera CF
    Clin Colorectal Cancer; 2008 Jul; 7(4):273-9. PubMed ID: 18650196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
    Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
    Vincenzi B; Santini D; Russo A; Gavasci M; Battistoni F; Dicuonzo G; Rocci L; Rosaria VM; Gebbia N; Tonini G
    Pharmacogenomics; 2007 Apr; 8(4):319-27. PubMed ID: 17391070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer.
    Mrabti H; De la Fouchardiere C; Desseigne F; Dussart S; Negrier S; Errihani H
    J Cancer Res Ther; 2009; 5(4):272-6. PubMed ID: 20160361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.
    Bouchahda M; Macarulla T; Spano JP; Bachet JB; Lledo G; Andre T; Landi B; Tabernero J; Karaboué A; Domont J; Levi F; Rougier P
    Crit Rev Oncol Hematol; 2008 Sep; 67(3):255-62. PubMed ID: 18400508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
    Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
    J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.